Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis
- PMID: 38818295
- PMCID: PMC11135270
- DOI: 10.4254/wjh.v16.i5.822
Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis
Abstract
Background: The gut-liver axis and bacterial translocation are important in cirrhosis, but there is no available universal biomarker of cellular bacterial translocation, for which presepsin may be a candidate.
Aim: To evaluate the relationship of the blood presepsin levels with the state of the gut microbiota in cirrhosis in the absence of obvious infection.
Methods: This study included 48 patients with Child-Pugh cirrhosis classes B and C and 15 healthy controls. The fecal microbiome was assessed using 16S rRNA gene sequencing. Plasma levels of presepsin were measured. A total of 22 patients received a probiotic (Saccharomyces boulardii) for 3 months.
Results: Presepsin levels were higher in patients with cirrhosis than in healthy individuals [342 (91-2875) vs 120 (102-141) pg/mL; P = 0.048]. Patients with elevated presepsin levels accounted for 56.3% of all included patients. They had lower levels of serum albumin and higher levels of serum total bilirubin and overall severity of cirrhosis as assessed using the Child-Pugh scale. Patients with elevated presepsin levels had an increased abundance of the main taxa responsible for bacterial translocation, namely Bacilli and Proteobacteria (including the main class Gammaproteobacteria and the minor taxa Xanthobacteraceae and Stenotrophomonas), and a low abundance of bacteria from the family Lachnospiraceae (including the minor genus Fusicatenibacter), which produce short-chain fatty acids that have a positive effect on intestinal barrier function. The presepsin level directly correlated with the relative abundance of Bacilli, Proteobacteria, and inversely correlated with the abundance of Lachnospiraceae and Propionibacteriaceae. After 3 months of taking the probiotic, the severity of cirrhosis on the Child-Pugh scale decreased significantly only in the group with elevated presepsin levels [from 9 (8-11) to 7 (6-9); P = 0.004], while there were no significant changes in the group with normal presepsin levels [from 8 (7-8) to 7 (6-8); P = 0.123]. A high level of presepsin before the prescription of the probiotic was an independent predictor of a greater decrease in Child-Pugh scores (P = 0.046), as well as a higher level of the Child-Pugh scale (P = 0.042), but not the C-reactive protein level (P = 0.679) according to multivariate linear regression analysis.
Conclusion: The level of presepsin directly correlates with the abundance in the gut microbiota of the main taxa that are substrates of bacterial translocation in cirrhosis. This biomarker, in the absence of obvious infection, seems important for assessing the state of the gut-liver axis in cirrhosis and deciding on therapy targeted at the gut microbiota in this disease.
Keywords: Dysbiosis; Gut; Gut-liver axis; Intestinal permeability; Leaky gut; Liver; Microbiota.
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: No conflicts of interest.
Figures


Similar articles
-
Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis.Int J Mol Sci. 2024 Feb 6;25(4):1988. doi: 10.3390/ijms25041988. Int J Mol Sci. 2024. PMID: 38396668 Free PMC article.
-
Gut Microbiota and Biomarkers of Intestinal Barrier Damage in Cirrhosis.Microorganisms. 2024 Feb 25;12(3):463. doi: 10.3390/microorganisms12030463. Microorganisms. 2024. PMID: 38543514 Free PMC article.
-
Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis.World J Gastroenterol. 2022 Mar 14;28(10):1067-1077. doi: 10.3748/wjg.v28.i10.1067. World J Gastroenterol. 2022. PMID: 35431497 Free PMC article.
-
Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?Diseases. 2019 Nov 12;7(4):58. doi: 10.3390/diseases7040058. Diseases. 2019. PMID: 31726747 Free PMC article. Review.
-
Gut microbiota and host metabolism in liver cirrhosis.World J Gastroenterol. 2015 Nov 7;21(41):11597-608. doi: 10.3748/wjg.v21.i41.11597. World J Gastroenterol. 2015. PMID: 26556989 Free PMC article. Review.
Cited by
-
Effect of Saccharomyces boulardii on Liver Diseases: A Systematic Review.Microorganisms. 2024 Aug 15;12(8):1678. doi: 10.3390/microorganisms12081678. Microorganisms. 2024. PMID: 39203520 Free PMC article. Review.
-
Presepsin in Hepatic Pathology: Bridging the Gap in Early Sepsis Detection.Diagnostics (Basel). 2025 Jul 25;15(15):1871. doi: 10.3390/diagnostics15151871. Diagnostics (Basel). 2025. PMID: 40804836 Free PMC article. Review.
References
-
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460. - PubMed
-
- Chandna S, Zarate ER, Gallegos-Orozco JF. Management of Decompensated Cirrhosis and Associated Syndromes. Surg Clin North Am. 2022;102:117–137. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials